A phase IIa, International, Multicenter, Open-label, Uncontrolled Study to Evaluate the Safety and Pharmacokinetics of 4x 375mh/m2 Intravenous Rituximab in Pediatric Patients with Severe Granulomatosis with Polyangiitis (Wegener's) or Microscopic Polyangiitis
A study for young patients with Wegeners granulomatosis or severe microscopic polyangiitis using study drug rituximab
Sponsor: Hoffmann-La Roche
Enrolling: Male and Female Patients
IRB Number: AAAO3002
U.S. Govt. ID: NCT01750697
Contact: Lisa Imundo: 212-305-4308 / lfi1@columbia.edu
Additional Study Information: The purpose of this study is to evaluate the safety and tolerability of a study drug called rituximab in pediatric patients with sever granulomatosis with polyangiitis (GPA) microscopic polyangiitis (MPA). Rituximab is used to treat people with cancer or arthritis. It has also been shown toimprove GPA (previously known as Wegeners granulomatosis) and MPA (microscopic polyangiitis)in adults, and we want to find out whether this medicine is also okay to use in children andadolescents with GPA or MPA.
This study is closed
Investigator
Lisa Imundo, MD
Do You Qualify?
Does your child have a diagnosis of granulomatosis with polyangiitis or diagnosis of microscopic polyangiitis? Yes No
Does your child have history of serious or chronic infection? Yes No
Does your child have a history of cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Lisa Imundo
lfi1@columbia.edu
212-305-4308